Eisenhauer EL - Search Results

1

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller DS, O'Malley DM, Percac-Lima S, Ratner E, Remmenga SW, Vargas R, Werner TL, Zsiros E, Burns JL, Engh AM. Armstrong DK, et al. Among authors: eisenhauer el. J Natl Compr Canc Netw. 2021 Feb 2;19(2):191-226. doi: 10.6004/jnccn.2021.0007. J Natl Compr Canc Netw. 2021. PMID: 33545690

2

Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.

O'Malley DM, Richardson DL, Rheaume PS, Salani R, Eisenhauer EL, McCann GA, Fowler JM, Copeland LJ, Cohn DE, Backes FJ. O'Malley DM, et al. Among authors: eisenhauer el. Gynecol Oncol. 2011 May 1;121(2):269-72. doi: 10.1016/j.ygyno.2011.01.009. Epub 2011 Feb 18. Gynecol Oncol. 2011. PMID: 21315428

3

Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer.

Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O'Malley DM, Fowler JM, Copeland LJ, Salani R. Nagel CI, et al. Among authors: eisenhauer el. Gynecol Oncol. 2012 Feb;124(2):221-4. doi: 10.1016/j.ygyno.2011.10.003. Epub 2011 Nov 4. Gynecol Oncol. 2012. PMID: 22055764 Free PMC article.

4

Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?

McCann GA, Smith B, Backes FJ, Rath K, Chacko S, Salani R, Eisenhauer E, Fowler JM, Cohn DE, O'Malley DM. McCann GA, et al. Gynecol Oncol. 2012 Nov;127(2):362-6. doi: 10.1016/j.ygyno.2012.08.001. Epub 2012 Aug 10. Gynecol Oncol. 2012. PMID: 22885866 Free PMC article.

5

Outcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian cancer.

Rath KS, Loseth D, Muscarella P, Phillips GS, Fowler JM, O'Malley DM, Cohn DE, Copeland LJ, Eisenhauer EL, Salani R. Rath KS, et al. Among authors: eisenhauer el. Gynecol Oncol. 2013 Apr;129(1):103-6. doi: 10.1016/j.ygyno.2013.01.021. Epub 2013 Jan 29. Gynecol Oncol. 2013. PMID: 23369942 Free PMC article.

6

Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?

Backes FJ, Richardson DL, McCann GA, Smith B, Salani R, Eisenhauer EL, Fowler JM, Copeland LJ, Cohn DE, O'Malley DM. Backes FJ, et al. Among authors: eisenhauer el. Int J Gynecol Cancer. 2013 Jun;23(5):833-8. doi: 10.1097/IGC.0b013e318290ea69. Int J Gynecol Cancer. 2013. PMID: 23640292

7

Feasibility of interval cytoreduction following neoadjuvant chemotherapy with carboplatin, weekly paclitaxel, and bevacizumab for advanced ovarian cancer--a phase 1 study.

Salani R, O'Malley DM, Copeland LJ, Cohn DE, Backes FJ, Fowler JM, Eisenhauer EL. Salani R, et al. Among authors: eisenhauer el. Int J Gynecol Cancer. 2014 May;24(4):682-6. doi: 10.1097/IGC.0000000000000107. Int J Gynecol Cancer. 2014. PMID: 24651631 Clinical Trial.

8

A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer.

Eisenhauer EL, Zanagnolo V, Cohn DE, Salani R, O'Malley DM, Sutton G, Callahan MJ, Cobb B, Fowler JM, Copeland LJ. Eisenhauer EL, et al. Gynecol Oncol. 2014 Aug;134(2):262-6. doi: 10.1016/j.ygyno.2014.05.030. Epub 2014 Jun 5. Gynecol Oncol. 2014. PMID: 24910452 Clinical Trial.

9

Documentation of Pregnancy Risk Assessment and Pregnancy Among Women Presenting for Gynecologic Oncology Consultation.

Crafton S, Nekkanti S, Lynch C, Cohn DE, Fowler JM, Copeland LJ, O'Malley DM, Salani R, Backes FJ, Eisenhauer EL. Crafton S, et al. Among authors: eisenhauer el. Int J Gynecol Cancer. 2016 Jan;26(1):35-42. doi: 10.1097/IGC.0000000000000576. Int J Gynecol Cancer. 2016. PMID: 26658364

10

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.

Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Chitiyo VC, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA III, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Schorge J, Stewart D, Thaker PH, Vargas R, Hendrickson AW, Werner TL, Zsiros E, Dwyer MA, Hang L. Armstrong DK, et al. Among authors: eisenhauer el. J Natl Compr Canc Netw. 2022 Sep;20(9):972-980. doi: 10.6004/jnccn.2022.0047. J Natl Compr Canc Netw. 2022. PMID: 36075393

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

66 results

Search Page